Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Blood (2025) 146 (Supplement 1): 4052.

https://doi.org/10.1182/blood-2025-4052

Published: 2025

Journal Articles

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Ava Amidei, Benjamin Diamond, Elizabeth Lyubchenko, Stephanie Fernandes, Bahar Fard, Lubna Nousheen, Marc Arribas-Layton, Adam Sciambi, Dickran Kazandjian, James Hoffman, Abhishek Pandey, Marcella Kaddoura, Brian Walker, Ola Landgren, David Coffey

Blood (2025) 146 (Supplement 1): 2157.

https://doi.org/10.1182/blood-2025-2157

Published: 2025

Journal Articles

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

Blood (2025) 146 (Supplement 1): 7483.

https://doi.org/10.1182/blood-2025-7483

Published: 2025

Journal Articles

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Shahrier Hossain, Adam Sperling, Jacob Laubach, Shannon Miller, Pedro Vianna, Emily Simpson, Madison Chuma, Brendan Fink, Samantha Geberth, Emily Magnavita, Jack Khouri, James Hoffman, Jonathan Kaufman, Vaishali Sanchorawala, Raymond Comenzo, Giada Bianchi

Blood (2025) 146 (Supplement 1): 5808.

https://doi.org/10.1182/blood-2025-5808

Published: 2025

Journal Articles

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

Blood (2025) 146 (Supplement 1): 7479.

https://doi.org/10.1182/blood-2025-7479

Published: 2025

Journal Articles

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

Blood (2025) 146 (Supplement 1): 251.

https://doi.org/10.1182/blood-2025-251

Published: 2025

Journal Articles

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Blood (2025) 146 (Supplement 1): 248.

https://doi.org/10.1182/blood-2025-248

Published: 2025

Journal Articles

Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes

Nathan Becker, Enze Liu, Zackary Sanborn, Attaya Suvannasankha, Kelvin Lee, Dickran Kazandjian, James Hoffman, Benjamin Diamond, Abhishek Pandey, Rafat Abonour, Ola Landgren, Lisa Munding, Aneta Mikulasova, Brian Walker

Blood (2025) 146 (Supplement 1): 3928.

https://doi.org/10.1182/blood-2025-3928

Published: 2025

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025

Journal Articles

Monoclonal gammopathy-related coagulopathies: A systematic analysis

Tessa Lavorgna, Thomas Plate, Diana Byrnes, Dickran Kazandjian, Benjamin Diamond, James Hoffman, Ola Landgren, Gerald Soff

Blood (2025) 146 (Supplement 1): 1305.

https://doi.org/10.1182/blood-2025-1305

Published: 2025

Journal Articles

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Blood (2025) 146 (Supplement 1): 4008.

https://doi.org/10.1182/blood-2025-4008

Published: 2025

Journal Articles

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Blood (2025) 146 (Supplement 1): 692.

https://doi.org/10.1182/blood-2025-692

Published: 2025

Journal Articles

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Ola Landgren, Benjamin Diamond, Abhishek Pandey, James Hoffman, David Coffey, Marcella Kaddoura, Brian Walker, Rabia Bukhari, Caterine Diaz, Stephanie Mompoint, Sindy Gutierrez, Kellye Koubek, Andrew Kowalski, Leslie Gallardo, Stephanie Fernandes, Sandra Mira, Massiel Cardo Lopez, Michelle Armogan, Dickran Kazandjian

Blood (2025) 146 (Supplement 1): 5775.

https://doi.org/10.1182/blood-2025-5775

Published: 2025

Journal Articles

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Angela Dispenzieri, MD, Jeff Zonder, MD, James Hoffman, MD, Sandy W. Wong, MD, Michaela Liedtke, MD, Rafat Abonour, MD, Anita D'Souza, MBBS, Charlene Lee, MSc, Sandhya Nair, PhD MSc, Ravi Potluri, PGDM, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Annette Lam, MSc, Maneesha Mehra, MPH

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140405

Published: 2020

Journal Articles

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Blood (2018) 132 (Supplement 1): 598.

https://doi.org/10.1182/blood-2018-99-116663

Published: 2018

Journal Articles

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Blood (2016) 128 (22): 491.

https://doi.org/10.1182/blood.V128.22.491.491

Published: 2016

Journal Articles

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Blood (2016) 128 (22): 3307.

https://doi.org/10.1182/blood.V128.22.3307.3307

Published: 2016

Journal Articles

Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

Sheeba K. Thomas, MD, Wael A. Harb, MD, Joseph Thaddeus Beck, MD, Gabrail Nashat, MD, M. Lia Palomba, MD, Stephen M Ansell, MD PhD, Herbert Eradat, MD, Edward N. Libby, III, MD, Ranjana H Advani, MD, Julio Hajdenberg, MD, Leonard T Heffner, MD, James Hoffman, MD, David H. Vesole, MD, Lindsey Simov, Nancy Wyant, Julie Brevard, MPH, James O'Leary, MD, Sudhir Agrawal, D.Phil

Blood (2015) 126 (23): 1540.

https://doi.org/10.1182/blood.V126.23.1540.1540

Published: 2015

Journal Articles

MAGE-A3 or NY-ESO1 Expression and Spontaneous Antibody Responses to NY-ESO1 in Newly Diagnosed Multiple Myeloma Patients Are Associated with Worse Overall Survival

Adam D Cohen, Ping Lu, Sacha Gnjatic, James Hoffman, Erika Ritter, Ping Zhou, Julie Teruya-Feldstein, Jodie Tassello, Nicole Hanson, Denise Frosina, Achim Jungbluth, Guenther Koehne, Hani Hassoun, Suresh Jhanwar, Heather Landau, Stephen Nimer, Raymond L. Comenzo

Blood (2008) 112 (11): 5110.

https://doi.org/10.1182/blood.V112.11.5110.5110

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Monoclonal gammopathy-related coagulopathies: A systematic analysis

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

MAGE-A3 or NY-ESO1 Expression and Spontaneous Antibody Responses to NY-ESO1 in Newly Diagnosed Multiple Myeloma Patients Are Associated with Worse Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only